{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:02:38Z","timestamp":1789401758923,"version":"build-2803163510"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012576","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012576","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.phrs.2026.108337","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:38:24Z","timestamp":1783640304000},"page":"108337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting the pathological tau N368 fragment: A pharmacological perspective on a novel immunotherapy for Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1306-6829","authenticated-orcid":false,"given":"Zhengjiang","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengtao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqing","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruikun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqiang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108337_bib1","doi-asserted-by":"crossref","first-page":"04156","DOI":"10.7189\/jogh.15.04156","article-title":"Global incidence trends and projections of Alzheimer disease and other dementias: an age-period-cohort analysis 2021","volume":"15","author":"Xu","year":"2025","journal-title":"J. Glob. Health"},{"issue":"1","key":"10.1016\/j.phrs.2026.108337_bib2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer's disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Mol. Neurodegener."},{"issue":"12","key":"10.1016\/j.phrs.2026.108337_bib3","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.molmed.2024.10.010","article-title":"Advancements and challenges in mouse models of Alzheimer's disease","volume":"30","author":"Qian","year":"2024","journal-title":"Trends Mol. Med."},{"issue":"5","key":"10.1016\/j.phrs.2026.108337_bib4","article-title":"Donanemab: Appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J. Prev. Alzheimer's. Dis."},{"issue":"4","key":"10.1016\/j.phrs.2026.108337_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40265-023-01851-2","article-title":"Lecanemab: First Approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.phrs.2026.108337_bib6","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer's Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"New. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.phrs.2026.108337_bib7","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s40120-024-00664-z","article-title":"Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years","volume":"13","author":"Wicker","year":"2024","journal-title":"Neurol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2026.108337_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"New. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108337_bib9","first-page":"535","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease, Alzheimer's & dementia: the journal of the Alzheimer'","volume":"14","author":"Jack","year":"2018","journal-title":"S. Assoc."},{"issue":"8","key":"10.1016\/j.phrs.2026.108337_bib10","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimer's. & Dement. J. Alzheimer's. Assoc."},{"issue":"4","key":"10.1016\/j.phrs.2026.108337_bib11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","article-title":"The Cellular Phase of Alzheimer's Disease","volume":"164","author":"De Strooper","year":"2016","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.phrs.2026.108337_bib12","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.14336\/AD.2022.0412","article-title":"Amyloid Cascade Hypothesis for the Treatment of Alzheimer's Disease: Progress and Challenges","volume":"13","author":"Wu","year":"2022","journal-title":"Aging Dis."},{"issue":"1","key":"10.1016\/j.phrs.2026.108337_bib13","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/s41467-022-34538-5","article-title":"Experimental evidence for temporal uncoupling of brain A\u03b2 deposition and neurodegenerative sequelae","volume":"13","author":"Rother","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108337_bib14","first-page":"43","article-title":"Alzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses","volume":"15","author":"Nasb","year":"2024","journal-title":"Aging Dis."},{"issue":"5","key":"10.1016\/j.phrs.2026.108337_bib15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108337_bib16","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1212\/01.WNL.0000063311.58879.01","article-title":"Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease","volume":"60","author":"Giannakopoulos","year":"2003","journal-title":"Neurology"},{"issue":"1-2","key":"10.1016\/j.phrs.2026.108337_bib17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000440842","article-title":"Tau Immunotherapy","volume":"16","author":"Sigurdsson","year":"2016","journal-title":"Neuro-Degener. Dis."},{"key":"10.1016\/j.phrs.2026.108337_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-025-01370-7","article-title":"Therapeutic targeting of neuroimmune mechanisms in neurodegeneration","author":"Monroe","year":"2026","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"14","key":"10.1016\/j.phrs.2026.108337_bib19","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006277","article-title":"Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease","volume":"91","author":"McDade","year":"2018","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.phrs.2026.108337_bib20","article-title":"Targeting Amyloid-\u03b2 Proteins as Potential Alzheimer's Disease Therapeutics: Anti-Amyloid Drug Discovery, Emerging Therapeutics, Clinical Trials and Implications for Public Health","volume":"18","author":"Abduljawad","year":"2025","journal-title":"Pharm. (Basel Switz. )"},{"issue":"3","key":"10.1016\/j.phrs.2026.108337_bib21","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0197-4580(95)00021-6","article-title":"Staging of Alzheimer's disease-related neurofibrillary changes","volume":"16","author":"Braak","year":"1995","journal-title":"Neurobiol. Aging"},{"issue":"11","key":"10.1016\/j.phrs.2026.108337_bib22","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/brain\/awab248","article-title":"Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages","volume":"144","author":"Pascoal","year":"2021","journal-title":"Brain a J. Neurol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108337_bib23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41583-018-0067-3","article-title":"Imaging the evolution and pathophysiology of Alzheimer disease","volume":"19","author":"Jagust","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2026.108337_bib24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/B978-0-323-98817-9.00029-6","article-title":"Passive tau-based immunotherapy for tauopathies","volume":"196","author":"Panza","year":"2023","journal-title":"Handb. Clin. Neurol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108337_bib25","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1007\/s12035-023-03867-x","article-title":"Complicated Role of Post-translational Modification and Protease-Cleaved Fragments of Tau in Alzheimer's Disease and Other Tauopathies","volume":"61","author":"Yang","year":"2024","journal-title":"Mol. Neurobiol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108337_bib26","article-title":"Tau biology, biomarkers, and therapeutics","volume":"11","author":"Frost","year":"2025","journal-title":"Alzheimers Dement. (N. Y"},{"issue":"12","key":"10.1016\/j.phrs.2026.108337_bib27","first-page":"5343","article-title":"Plasma and CSF concentrations of N-terminal tau fragments associate with in vivo neurofibrillary tangle burden, Alzheimer's & dementia: the journal of the Alzheimer","volume":"19","author":"Lantero-Rodriguez","year":"2023","journal-title":"S. Assoc."},{"issue":"11","key":"10.1016\/j.phrs.2026.108337_bib28","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm.3700","article-title":"Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease","volume":"20","author":"Zhang","year":"2014","journal-title":"Nat. Med."},{"issue":"18","key":"10.1016\/j.phrs.2026.108337_bib29","doi-asserted-by":"crossref","first-page":"9094","DOI":"10.1073\/pnas.1901348116","article-title":"Delta-secretase-cleaved Tau antagonizes TrkB neurotrophic signalings, mediating Alzheimer's disease pathologies","volume":"116","author":"Xiang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2026.108337_bib30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13024-025-00854-9","article-title":"Immunotherapy against tau fragment diminishes AD pathology, improving synaptic function and cognition","volume":"20","author":"Xiang","year":"2025","journal-title":"Mol. Neurodegener."},{"issue":"40","key":"10.1016\/j.phrs.2026.108337_bib31","doi-asserted-by":"crossref","first-page":"38980","DOI":"10.1074\/jbc.M305930200","article-title":"Multistep autoactivation of asparaginyl endopeptidase in vitro and in vivo","volume":"278","author":"Li","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.108337_bib32","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.biochi.2015.09.022","article-title":"Structure and function of legumain in health and disease","volume":"122","author":"Dall","year":"2016","journal-title":"Biochimie"},{"issue":"8","key":"10.1016\/j.phrs.2026.108337_bib33","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nsmb.3433","article-title":"Asparagine endopeptidase cleaves \u03b1-synuclein and mediates pathologic activities in Parkinson's disease","volume":"24","author":"Zhang","year":"2017","journal-title":"Nat. Struct. & Mol. Biol."},{"key":"10.1016\/j.phrs.2026.108337_bib34","doi-asserted-by":"crossref","first-page":"8762","DOI":"10.1038\/ncomms9762","article-title":"Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer's disease","volume":"6","author":"Zhang","year":"2015","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108337_bib35","doi-asserted-by":"crossref","DOI":"10.1186\/s40035-019-0179-3","article-title":"\u03b4-secretase in neurodegenerative diseases: mechanisms, regulators and therapeutic opportunities","volume":"9","author":"Zhang","year":"2020","journal-title":"Transl. Neurodegener."},{"issue":"8","key":"10.1016\/j.phrs.2026.108337_bib36","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/s12276-020-00494-7","article-title":"Delta-secretase cleavage of Tau mediates its pathology and propagation in Alzheimer's disease","volume":"52","author":"Kang","year":"2020","journal-title":"Exp. & Mol. Med."},{"issue":"24","key":"10.1016\/j.phrs.2026.108337_bib37","doi-asserted-by":"crossref","first-page":"17495","DOI":"10.1074\/jbc.M112.446070","article-title":"Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease","volume":"288","author":"Basurto-Islas","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.108337_bib38","doi-asserted-by":"crossref","first-page":"14740","DOI":"10.1038\/ncomms14740","article-title":"Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer's disease","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.phrs.2026.108337_bib39","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41386-023-01774-2","article-title":"Inhibition of asparagine endopeptidase (AEP) effectively treats sporadic Alzheimer's disease in mice","volume":"49","author":"Qian","year":"2024","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108337_bib40","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molmed.2025.01.009","article-title":"Development of asparagine endopeptidase inhibitors for treating neurodegenerative diseases","volume":"31","author":"Meng","year":"2025","journal-title":"Trends Mol. Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108337_bib41","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4103\/1673-5374.382253","article-title":"STAT3 ameliorates truncated tau-induced cognitive deficits","volume":"19","author":"Zhang","year":"2024","journal-title":"Neural Regen. Res."},{"issue":"4","key":"10.1016\/j.phrs.2026.108337_bib42","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/s41594-022-00745-3","article-title":"Tau modification by the norepinephrine metabolite DOPEGAL stimulates its pathology and propagation","volume":"29","author":"Kang","year":"2022","journal-title":"Nat. Struct. & Mol. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108337_bib43","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.celrep.2019.06.054","article-title":"Deficiency in BDNF\/TrkB Neurotrophic Activity Stimulates \u03b4-Secretase by Upregulating C\/EBP\u03b2 in Alzheimer's Disease","volume":"28","author":"Wang","year":"2019","journal-title":"Cell. Rep."},{"issue":"12","key":"10.1016\/j.phrs.2026.108337_bib44","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nrn2738","article-title":"TrkB signalling pathways in LTP and learning","volume":"10","author":"Minichiello","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"issue":"12","key":"10.1016\/j.phrs.2026.108337_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70138","article-title":"Impact and Mechanisms of Action of BDNF on Neurological Disorders, Cancer, and Cardiovascular Diseases","volume":"30","author":"Lei","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.phrs.2026.108337_bib46","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.neuropharm.2013.04.005","article-title":"BDNF-induced local protein synthesis and synaptic plasticity","volume":"76","author":"Leal","year":"2014","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.phrs.2026.108337_bib47","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/00005072-199907000-00007","article-title":"BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies","volume":"58","author":"Ferrer","year":"1999","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.phrs.2026.108337_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104540","article-title":"Brain-derived neurotrophic factor (BDNF) and TrkB hippocampal gene expression are putative predictors of neuritic plaque and neurofibrillary tangle pathology","volume":"132","author":"Ginsberg","year":"2019","journal-title":"Neurobiol. Dis."},{"issue":"16","key":"10.1016\/j.phrs.2026.108337_bib49","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99007","article-title":"BDNF inhibits neurodegenerative disease-associated asparaginyl endopeptidase activity via phosphorylation by AKT","volume":"3","author":"Wang","year":"2018","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.phrs.2026.108337_bib50","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41380-018-0286-z","article-title":"\u03b4-Secretase-cleaved Tau stimulates A\u03b2 production via upregulating STAT1-BACE1 signaling in Alzheimer's disease","volume":"26","author":"Zhang","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2026.108337_bib51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-021-00430-x","article-title":"Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics","volume":"16","author":"Zetterberg","year":"2021","journal-title":"Mol. Neurodegener."},{"issue":"2","key":"10.1016\/j.phrs.2026.108337_bib52","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/brain\/awaa373","article-title":"CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease","volume":"144","author":"Horie","year":"2021","journal-title":"Brain a J. Neurol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108337_bib53","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108337_bib54","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/brain\/awab481","article-title":"N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases","volume":"145","author":"Snellman","year":"2022","journal-title":"Brain a J. Neurol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108337_bib55","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","article-title":"Advantages and disadvantages of the use of the CSF Amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer's Disease","volume":"11","author":"Hansson","year":"2019","journal-title":"Alzheimer's. Res. & Ther."},{"issue":"3","key":"10.1016\/j.phrs.2026.108337_bib56","article-title":"CSF tau and the CSF tau\/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)","author":"Ritchie","year":"2017","journal-title":"Cochrane Database Syst. Rev. 3"},{"issue":"1","key":"10.1016\/j.phrs.2026.108337_bib57","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/JAD-181152","article-title":"Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases","volume":"68","author":"Seino","year":"2019","journal-title":"J. Alzheimers Dis."},{"issue":"6","key":"10.1016\/j.phrs.2026.108337_bib58","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114022","article-title":"Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau","volume":"13","author":"Mattsson-Carlgren","year":"2021","journal-title":"EMBO Mol. Med."},{"issue":"3","key":"10.1016\/j.phrs.2026.108337_bib59","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","article-title":"A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease","volume":"26","author":"Barth\u00e9lemy","year":"2020","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.phrs.2026.108337_bib60","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114398","article-title":"Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers","volume":"13","author":"Ossenkoppele","year":"2021","journal-title":"EMBO Mol. Med."},{"issue":"2","key":"10.1016\/j.phrs.2026.108337_bib61","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/brain\/awz346","article-title":"Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology","volume":"143","author":"Blennow","year":"2020","journal-title":"Brain a J. Neurol."},{"issue":"7662","key":"10.1016\/j.phrs.2026.108337_bib62","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature23002","article-title":"Cryo-EM structures of tau filaments from Alzheimer's disease","volume":"547","author":"Fitzpatrick","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.phrs.2026.108337_bib63","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1007\/s00259-018-4242-6","article-title":"Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease","volume":"46","author":"Leuzy","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.phrs.2026.108337_bib64","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13195-022-01142-0","article-title":"CSF tau368\/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals","volume":"14","author":"Simr\u00e9n","year":"2022","journal-title":"Alzheimer's. Res. & Ther."},{"issue":"12","key":"10.1016\/j.phrs.2026.108337_bib65","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/s41591-022-02075-9","article-title":"CSF tau microtubule-binding region identifies pathological changes in primary tauopathies","volume":"28","author":"Horie","year":"2022","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.phrs.2026.108337_bib66","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"issue":"3","key":"10.1016\/j.phrs.2026.108337_bib67","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","article-title":"Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model","volume":"53","author":"Yoshiyama","year":"2007","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.phrs.2026.108337_bib68","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","article-title":"Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction","volume":"39","author":"Oddo","year":"2003","journal-title":"Neuron"},{"issue":"8","key":"10.1016\/j.phrs.2026.108337_bib69","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.neuron.2024.01.024","article-title":"Mechanisms of sex differences in Alzheimer's disease","volume":"112","author":"Lopez-Lee","year":"2024","journal-title":"Neuron"},{"issue":"15","key":"10.1016\/j.phrs.2026.108337_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25158485","article-title":"Sex and Gender Differences in Alzheimer's Disease: Genetic, Hormonal, and Inflammation Impacts","volume":"25","author":"Kolahchi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.phrs.2026.108337_bib71","first-page":"1966","article-title":"Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060), Alzheimer's & dementia: the journal of the Alzheimer","volume":"17","author":"Rajan","year":"2021","journal-title":"S. Assoc."},{"issue":"1","key":"10.1016\/j.phrs.2026.108337_bib72","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41582-025-01162-y","article-title":"Microglial phagocytosis in Alzheimer disease","volume":"22","author":"Brown","year":"2026","journal-title":"Nat. Rev. Neurol."},{"issue":"6639","key":"10.1016\/j.phrs.2026.108337_bib73","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1126\/science.abn1366","article-title":"Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models","volume":"379","author":"Mukadam","year":"2023","journal-title":"Science (New York N. Y. )"},{"issue":"3","key":"10.1016\/j.phrs.2026.108337_bib74","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1073\/pnas.1607215114","article-title":"Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation","volume":"114","author":"McEwan","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"46","key":"10.1016\/j.phrs.2026.108337_bib75","doi-asserted-by":"crossref","first-page":"19985","DOI":"10.1073\/pnas.1014074107","article-title":"Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21)","volume":"107","author":"Mallery","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108337_bib76","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.semcdb.2021.09.012","article-title":"Targeted protein degradation using intracellular antibodies and its application to neurodegenerative disease","volume":"126","author":"Benn","year":"2022","journal-title":"Semin. Cell. Dev. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108337_bib77","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/imr.12363","article-title":"TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity","volume":"268","author":"Foss","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.phrs.2026.108337_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02049","article-title":"TRIM21-From Intracellular Immunity to Therapy","volume":"10","author":"Foss","year":"2019","journal-title":"Front. Immunol."},{"issue":"545","key":"10.1016\/j.phrs.2026.108337_bib79","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1359","article-title":"Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys","volume":"12","author":"Kariolis","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"545","key":"10.1016\/j.phrs.2026.108337_bib80","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1163","article-title":"Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice","volume":"12","author":"Ullman","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"19","key":"10.1016\/j.phrs.2026.108337_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/cells14191506","article-title":"Tau-Targeted Therapeutic Strategies: Mechanistic Targets, Clinical Pipelines, and Analysis of Failures","volume":"14","author":"Shen","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2026.108337_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104707","article-title":"Advances and considerations in AD tau-targeted immunotherapy","volume":"134","author":"Bittar","year":"2020","journal-title":"Neurobiol. Dis."},{"issue":"12","key":"10.1016\/j.phrs.2026.108337_bib83","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108337_bib84","article-title":"Tau in Alzheimer's disease: Shaping the future patient journey","volume":"13","author":"Mummery","year":"2026","journal-title":"J. Prev. Alzheimer's. Dis."},{"issue":"26","key":"10.1016\/j.phrs.2026.108337_bib85","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1016\/j.cell.2025.11.033","article-title":"The evolving landscape of Alzheimer's disease therapy: From A\u03b2 to tau","volume":"188","author":"Courade","year":"2025","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.phrs.2026.108337_bib86","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108337_bib87","article-title":"Development of tau phosphorylation-targeting therapies for the treatment of neurodegenerative diseases","volume":"1","author":"Su","year":"2024","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.phrs.2026.108337_bib88","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"au-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2026.108337_bib89","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-026-04273-1","article-title":"The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial","author":"Mummery","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2026.108337_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1401471","article-title":"TRIM21 and Fc-engineered antibodies: decoding its complex antibody binding mode with implications for viral neutralization","volume":"15","author":"Reusch","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108337_bib91","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","article-title":"Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain","volume":"11","author":"Pardridge","year":"2019","journal-title":"Front. Aging Neurosci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108337_bib92","doi-asserted-by":"crossref","first-page":"8","DOI":"10.14735\/amko20208","article-title":"Side Effects and Efficacy of Immunotherapy","volume":"33","author":"Fiala","year":"2020","journal-title":"Klin. Onkol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108337_bib93","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.soc.2019.02.009","article-title":"Immunotherapy Toxicities","volume":"28","author":"Sanchez","year":"2019","journal-title":"Surg. Oncol. Clin. North. Am."},{"issue":"Pt 1","key":"10.1016\/j.phrs.2026.108337_bib94","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1107\/S1744309111048020","article-title":"Activation of legumain involves proteolytic and conformational events, resulting in a context- and substrate-dependent activity profile","volume":"68","author":"Dall","year":"2012","journal-title":"Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun."},{"issue":"2(2","key":"10.1016\/j.phrs.2026.108337_bib95","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/jnc.13583","article-title":"Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies","volume":"139","author":"Golde","year":"2016","journal-title":"J. Neurochem."},{"issue":"10","key":"10.1016\/j.phrs.2026.108337_bib96","article-title":"Alzheimer Combination Therapies: Overview and Scenarios","volume":"12","author":"Cummings","year":"2025","journal-title":"J. Prev. Alzheimer's. Dis."},{"issue":"8","key":"10.1016\/j.phrs.2026.108337_bib97","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40263-024-01103-1","article-title":"Alzheimer's Disease: Combination Therapies and Clinical Trials for Combination Therapy Development","volume":"38","author":"Cummings","year":"2024","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.phrs.2026.108337_bib98","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3233\/JAD-215680","article-title":"Combination Therapy in Alzheimer's Disease: Is It Time?","volume":"87","author":"Salehipour","year":"2022","journal-title":"J. Alzheimers Dis."},{"issue":"3","key":"10.1016\/j.phrs.2026.108337_bib99","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/npp.2013.243","article-title":"7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer's disease","volume":"39","author":"Zhang","year":"2014","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108337_bib100","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1073\/pnas.1718683115","article-title":"The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer's disease","volume":"115","author":"Chen","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108337_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102883","article-title":"Unravelling neuronal death mechanisms: The role of cytokines and chemokines in immune imbalance in Alzheimer's disease progression","volume":"112","author":"Kumari","year":"2025","journal-title":"Ageing Res. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2026.108337_bib102","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13024-023-00672-x","article-title":"Mechanism and therapeutic potential of targeting cGAS-STING signaling in neurological disorders","volume":"18","author":"Huang","year":"2023","journal-title":"Mol. Neurodegener."},{"issue":"2","key":"10.1016\/j.phrs.2026.108337_bib103","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s43587-022-00337-2","article-title":"Activation of innate immune cGAS-STING pathway contributes to Alzheimer's pathogenesis in 5\u00d7FAD mice","volume":"3","author":"Xie","year":"2023","journal-title":"Nat. Aging"},{"issue":"1","key":"10.1016\/j.phrs.2026.108337_bib104","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13024-025-00815-2","article-title":"The neuroimmune nexus: unraveling the role of the mtDNA-cGAS-STING signal pathway in Alzheimer's disease","volume":"20","author":"Quan","year":"2025","journal-title":"Mol. Neurodegener."},{"issue":"3","key":"10.1016\/j.phrs.2026.108337_bib105","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40120-022-00373-5","article-title":"The Potential Economic Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.phrs.2026.108337_bib106","article-title":"The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint","volume":"29","author":"J\u00f6nsson","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.phrs.2026.108337_bib107","article-title":"Lifetime cost-effectiveness of lecanemab for early Alzheimer's disease","volume":"14","author":"Jiang","year":"2026","journal-title":"Front. Public. Health"},{"issue":"5","key":"10.1016\/j.phrs.2026.108337_bib108","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol."},{"issue":"8100","key":"10.1016\/j.phrs.2026.108337_bib109","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41586-025-10018-w","article-title":"Biofluid biomarkers in Alzheimer's disease and other neurodegenerative dementias","volume":"650","author":"Zetterberg","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108337_bib110","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-neuro-072116-031153","article-title":"Propagation of Tau Aggregates and Neurodegeneration","volume":"40","author":"Goedert","year":"2017","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2026.108337_bib111","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev-pathmechdis-051222-120750","article-title":"Neurodegenerative Disease Tauopathies","volume":"19","author":"Creekmore","year":"2024","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.phrs.2026.108337_bib112","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/B978-0-323-98817-9.00015-6","article-title":"The tauopathies","volume":"196","author":"Devi","year":"2023","journal-title":"Handb. Clin. Neurol."},{"issue":"18","key":"10.1016\/j.phrs.2026.108337_bib113","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1021\/acschemneuro.3c00437","article-title":"Insight into the Binding of First- and Second-Generation PET Tracers to 4R and 3R\/4R Tau Protofibrils","volume":"14","author":"Li","year":"2023","journal-title":"ACS Chem. Neurosci."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:03:39Z","timestamp":1789398219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":113,"alternative-id":["S1043661826002525"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108337","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the pathological tau N368 fragment: A pharmacological perspective on a novel immunotherapy for Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108337"}}